Saturday 17 October 2026 Export QDEL’s income statement to Excel — free account

QuidelOrtho Corporation

QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024. In the quarter to June 2026, revenue grew 2.77%, EPS grew 63.9%, free cash flow fell 61.5% and total debt rose 10.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

12.94 0.97 −6.97%

Follow QDEL

Alert me

Market cap: $953.9M
P/E: 0.0×
Fwd P/E: −9.0×
Dividend yield: —
F-score: 6/9
Altman Z: 0.11
Beneish M: −3.12
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.25

Total sells 0.11

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	1	—	3	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.50%

Capital & Financial Ratios $m

Market Cap 953.88

Revenue 2,674.20

Net Income (1,048.40)

Free Cash Flow (211.20)

Net Debt 2,767.70

Current Ratio 1.39

Debt/Equity 1.63

P/E ratio 0.00

Fwd P/E (8.96)

P/S ratio 0.33

P/B ratio 0.50

Past 5Y EPS Growth —

This Y EPS Growth (63.61%)

Next Y EPS Growth 85.11%

Next Y revenue growth (6.82%)

Next 5Y EPS Growth (4.59%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.03%

10-year low 10-year high

P/B against its own 10 years 2.29%

10-year low 10-year high

EV/Sales against its own 10 years 4.98%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	167	98	170	123
Receivables	303	282	417	352
Inventory	578	534	578	619
Other	—	42	32	32
	1,311	1,219	1,447	1,377

	2023	2024	2025	Q'26
Payables	295	246	279	237
ST’ Debt	140	342	178	356
Other	303	289	377	310
	834	999	966	993

Compound Annual Growth %

	10y	5y	3y
Sales	30.13%	10.44%	(5.80%)
Cash Flow	11.05%	(30.08%)	(50.84%)
Earnings	0.00%	0.00%	0.00%
Book Value	24.27%	7.58%	(26.99%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	620	631	—	—	—
’25	693	614	700	724	2,730
’24	711	637	727	708	2,783
’23	846	665	744	743	2,998
’22	1,002	613	784	866	3,266
’21	375	177	510	637	1,699
’20	175	202	476	809	1,662

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(33)	(111)	—	—	—
’25	66	(47)	(45)	132	105
’24	(1)	(98)	118	64	83
’23	189	(31)	42	80	280
’22	501	225	(10)	169	885
’21	585	(178)	77	321	806
’20	61	59	70	439	630

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(67)	(136)	—	—	—
’25	9	(84)	(95)	87	(83)
’24	(67)	(133)	71	26	(103)
’23	123	(82)	(2)	32	71
’22	478	199	(40)	108	744
’21	507	(253)	(30)	289	513
’20	55	51	48	410	565

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.35)	(1.36)	—	—	—
’25	(0.19)	(3.77)	(10.78)	(1.92)	(16.69)
’24	(25.50)	(2.20)	(0.30)	(2.28)	(30.16)
’23	0.73	(0.80)	(0.19)	0.10	(0.15)
’22	11.31	0.36	0.28	0.45	9.56
’21	4.09	0.45	5.08	6.85	16.43
’20	0.93	1.55	5.33	10.78	18.60

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	13.21	18.25	41.50	46.71	71.90	103.31	66.88	57.54	29.74	19.50	Analyst estimates 2026–2028 Powerpack
	High	23.94	46.14	77.63	75.18	306.72	265.00	135.90	98.67	75.82	49.45
People
People	Employees	627	1,193	1,224	1,250	1,370	1,600	7,000	7,100	6,600	6,500
	Revenue/emp, $m	0.31	0.23	0.43	0.43	1.21	1.06	0.47	0.42	0.42	0.42
Income, $m
Income, $m	Revenue	192	278	522	535	1,662	1,699	3,266	2,998	2,783	2,730
	Gross margin, %	58.31	56.22	60.45	59.98	81.62	75.26	59.28	49.94	46.23	46.67
	EBT	(16)	(8)	63	77	1,040	900	736	(29)	(2,131)	(1,108)
	EBT margin, %	(8.45)	(2.89)	12.14	14.43	62.60	53.00	22.53	(0.97)	(76.59)	(40.57)
	Net income	(14)	(8)	74	73	810	704	549	(10)	(2,052)	(1,132)
	Depreciation	29	39	60	58	49	53	284	457	2,276	1,143
Per share, $
Per share, $	Revenue	5.86	8.23	13.75	13.09	39.47	40.35	57.50	44.88	41.41	40.27
	Earnings	(0.42)	(0.24)	1.95	1.78	19.24	16.74	9.66	(0.15)	(30.16)	(16.69)
	Cash flow	0.36	0.82	3.59	3.29	14.96	19.14	15.59	4.19	1.24	1.55
	Capex	(0.36)	(0.52)	(0.83)	(0.67)	(1.54)	(6.95)	(2.48)	(3.13)	(2.76)	(2.78)
	Free cash flow	0.00	0.30	2.75	2.63	13.42	12.19	13.11	1.06	(1.53)	(1.22)
	Book value	6.13	6.73	11.20	13.70	31.66	45.83	86.88	74.94	44.41	28.33
	Shares, m	33	34	38	41	42	42	57	67	67	68
Valuation, ×
Valuation, ×	P/E	0.00	0.00	24.66	42.15	9.34	8.04	6.76	0.00	0.00	0.00
	P/S	3.56	5.40	3.55	5.73	4.55	3.35	1.48	1.67	1.08	0.71
	P/B	3.40	6.60	4.36	5.48	5.68	2.95	0.98	1.00	1.00	1.01
	EV/Sales	3.43	6.70	3.58	5.85	4.32	2.86	2.18	2.41	1.93	1.62
	EV/FCF	(1,307.70)	190.01	17.95	29.30	12.73	9.47	9.57	102.70	(52.11)	(52.95)
Cash, $m
Cash, $m	Operating cash flow	12	28	136	134	630	806	885	280	83	105
	Capex	(12)	(18)	(32)	(27)	(65)	(293)	(141)	(209)	(186)	(188)
	Free cash flow	0	10	105	107	565	513	744	71	(103)	(83)
Balance, $m
Balance, $m	Working capital	192	203	34	96	805	1,117	568	477	220	481
	Total debt	144	397	107	118	113	1	2,638	2,415	2,483	2,650
	Net debt	(25)	361	63	65	(377)	(828)	2,293	2,247	2,385	2,480
	Shareholders’ equity	201	227	426	560	1,333	1,929	4,935	5,006	2,985	1,921
Returns, %
Returns, %	ROA	(3.47)	(1.23)	8.52	8.49	58.25	32.74	9.72	(0.12)	(27.38)	(18.56)
	ROIC	(1.58)	1.01	12.26	9.27	69.34	51.40	7.30	1.20	(22.83)	(13.05)
	ROE	(6.59)	(3.82)	22.73	14.80	85.63	43.17	15.99	(0.20)	(51.36)	(46.15)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
QDEL QuidelOrtho Corporation	$953.9M	— (loss-making)	— (loss-making)	+2.77% (above 0%: growing)	n/m	−61.45% (below 0%: shrinking)	43.26%	(3.46%)
BBNX Beta Bionics, Inc.	$933.8M	— (loss-making)	— (loss-making)	+37.76% (above 0%: growing)	n/m	−1.87% (below 0%: shrinking)	59.04%	(79.90%)	Compare
SIBN SiBone	$892.3M	— (loss-making)	— (loss-making)	+15.18% (above 0%: growing)	n/m	+60.12% (above 0%: growing)	79.54%	(8.58%)	Compare
AHCO AdaptHealth Corp.	$871.2M	— (loss-making)	13.2×	+12.66% (above 0%: growing)	n/m	−128.56% (below 0%: shrinking)	14.08%	(18.61%)	Compare
Median of peers	$1.0B	—	20.2×	+13.92%	—	−13.15%	61.54%	(13.59%)

All 149 Medical Devices stocks →

QuidelOrtho Corporation (QDEL) key facts

Concern: QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024.
QuidelOrtho Corporation (QDEL) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, QDEL traded at $12.94, a market capitalization of $953.9 million.
Return on equity was −46.2% and debt-to-equity 1.63.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.